https://web.archive.org/web/20200204175556/http://www.whiov.ac.cn/kyjz_105338/202002/t20200204_5497136.html
Chinese scholars have made important progress in anti-2019 new coronavirus drug screening
Recently, the Wuhan Institute of Virology/Biosafety Science Research Center of the Chinese Academy of Sciences and the National Emergency Prevention and Control Drug Engineering Technology Research Center of the Academy of Military Medicine of the Academy of Military Sciences conducted a joint study, and achieved results in drug screening for the suppression of the 2019 novel coronavirus (2019-nCoV) Important progress. Related research results were published under the title "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro" ("Remdesivir and chloroquine phosphate can effectively inhibit the new coronavirus (2019-nCoV) in vitro") In Cell Research ("Cell Research"), an internationally renowned academic journal with independent intellectual property rights in China.
The study showed that on Vero E6 cells, Remdesivir (GS-5734) has a half effective concentration of 2019-nCoV EC50=0.77 uM (micromole per liter), the selection index SI is greater than 129; Chloroquine phosphate (Chloroquine) ) EC50=1.13 uM, SI is greater than 88, indicating that the above two drugs can effectively inhibit 2019-nCoV infection at the cellular level, and their effects in humans have yet to be clinically verified.
Remdesivir (GS-5734) is a nucleoside analogue, currently in the Congo (DRC) phase II and III clinical studies for the treatment of Ebola hemorrhagic fever. Chloroquine phosphate (Chloroquine) has been used for the treatment of malaria since the 1940s and later for the treatment of rheumatoid arthritis. The preliminary results of the above two drugs effectively inhibiting the 2019 novel coronavirus infection at the cellular level have previously been reported to relevant national, provincial and municipal departments in various forms. In order to serve the prevention and control of the epidemic, the two parties jointly declared: Among the above-mentioned drugs with anti-2019 new coronavirus effects, we will not apply for related patents for the drug chloroquine phosphate that has been marketed in China and can be fully supplied independently, in order to encourage related The enthusiasm of enterprises to participate in the prevention and control of the epidemic; for the drug Remdesivir, which is not yet on the market in China and has intellectual property barriers, we applied for a Chinese invention patent on January 21 from the perspective of protecting national interests in accordance with international practices ( Anti-2019 novel coronavirus use), and will enter the world's major countries through the PCT (Patent Cooperation Agreement) route. If relevant foreign companies intend to contribute to the prevention and control of the epidemic in our country, we both agree that if the country needs it, we will not require the implementation of the rights claimed by the patent for the time being. We hope to cooperate with foreign pharmaceutical companies to contribute to the prevention and control of the epidemic. force.
Researcher Wang Manli of Wuhan Institute of Virology, Associate Researcher Cao Ruiyuan of National Emergency Prevention and Control Drug Engineering Research Center of Military Medical Research Institute, Associate Researcher Zhang Leipi, Associate Researcher Yang Xinglou of Wuhan Institute of Virology are the co-first authors of the paper, researcher Xiao Gengfu of Wuhan Institute of Virology, Researcher Zhong Wu of the National Emergency Prevention and Control Drug Engineering Technology Research Center of the Academy of Military Medical Sciences and researcher Hu Zhihong of Wuhan Institute of Virology are the co-corresponding authors, and Liu Jia, Xu Mingyue, Shi Zhengli and others are the co-authors. Participants in the project are Wang Xi, Wu Yan, Shang Weijuan, Zhang Huanyu, Li Yufeng, Hu Hengrui, Jiang Xiaming, Sun Yuan from Wuhan Institute of Virology. This work has been strongly supported by the National Virus Resource Bank and Wuhan National Biosafety Laboratory, as well as the "Major New Drug Creation" National Science and Technology Major Project (2018ZX09711003), the National Natural Science Foundation of China Innovation Group Project (31621061) and Hubei Province 2019 New Type Pneumonia Emergency Technology Funding for research projects.
Link to the paper: https://www.nature.com/articles/s41422-020-0282-0